## Dacarbazine

**Section:** 8. Immunomodulators and antineoplastics  >  8.2. Antineoplastics and supportive medicines  >  8.2.1. Cytotoxic medicines

### Indication
- Hodgkin lymphoma

### INN
- Dacarbazine

### Medicine type
- Chemical agent

### List type
- Complementary (EML)
- (EMLc)

### Formulations
- Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

### EML status history
- First added in 1989 (TRS 796)
- Changed in 2002 (TRS 914)
- Changed in 2007 (TRS 950)
- Changed in 2011 (TRS 965)
- Changed in 2015 (TRS 994)
- Changed in 2023 (TRS 1049)

### Sex
- All

### Age
- Also recommended for children

### Therapeutic alternatives
- The recommendation is for this specific medicine

### Patent information
- Patents have expired in most jurisdictions
  - Read more about patents.

### Tags
- Cancer

### Wikipedia
- Dacarbazine

### DrugBank
- Dacarbazine

---

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional strength formulation of dacarbazine powder for injection (200 mg in vial) to the EML and EMLc.

[Expert Committee report](#)